0
0
NEW DELHI — In a major update presented to Parliament on July 30, 2026, India’s Department of Atomic Energy (DAE) unveiled a comprehensive overview of its expanding footprint in the medical sector. Through the indigenous development of specialized radioisotopes and target-specific radiopharmaceuticals, the agency is actively reshaping the landscape of affordable cancer care, cardiac diagnostics, and neurological imaging across the country.
The initiative—driven primarily by research units at the Bhabha Atomic Research Centre (BARC) in Mumbai and distributed via the Board of Radiation & Isotope Technology (BRIT)—aims to eliminate reliance on expensive foreign imports. By harnessing high-level nuclear material and localized reactor networks, medical institutions are now receiving domestically produced, life-saving diagnostic and therapeutic agents at a fraction of international prices.
The Frontier of Precision Medicine: How Radiopharmaceuticals Work
Unlike traditional radiation therapy—where high-energy beams are directed from outside the body toward a tumor—nuclear medicine operates on a molecular level. Doctors combine a tiny, safe amount of a radioactive isotope with a biological compound (known as a ligand). Once injected, this drug zeroes in on specific receptors found predominantly on diseased cells.
[ Radioactive Isotope ] + [ Molecular Ligand ] = Target-Specific Radiopharmaceutical
↓ ↓
Emits detectable signal (Diagnosis) Delivers localized radiation (Therapy)
Depending on the isotope selected, the compound serves one of two functions:
-
Diagnostic Imaging: Emits mild gamma rays or positrons detected by specialized scanners (PET or SPECT), mapping out the exact location and extent of tumors or tissue damage.
-
Targeted Radiotherapy: Delivers a concentrated dose of cell-destroying radiation directly inside cancerous cells, sparing healthy surrounding tissue.
“Targeted radionuclide therapy functions like a smart missile,” explains Dr. Ananya Mukherjee, a senior oncologist independent of the government program. “By attaching an isotope to a molecule that selectively binds to tumor markers, we can hit advanced or metastasized cancers that standard surgery or chemotherapy cannot easily reach. Making these agents locally available radically changes what we can offer patients in late-stage illness.”
Key Breakthroughs in Prostate and Gastrointestinal Cancers
Prostate cancer remains one of the most common malignancies affecting men globally. The DAE’s recent achievements highlight major steps forward in both diagnosing and treating this condition:
-
Prostate Cancer Diagnosis ($^{68}\text{Ga-PSMA-11}$): Developed as an import substitute, this radiopharmaceutical binds to the Prostate-Specific Membrane Antigen (PSMA), enabling high-resolution PET imaging that catches micro-metastases far earlier than conventional scans.
-
Prostate Cancer Therapy ($^{177}\text{Lu-PSMA-617}$): Once disease spread is confirmed, doctors utilize this therapeutic compound, which delivers localized beta radiation straight to PSMA-expressing tumor sites.
Beyond prostate health, the DAE has deployed ligands targeting neuroendocrine tumors ($^{177}\text{Lu-DOTA-TATE}$), non-Hodgkin’s lymphoma ($^{177}\text{Lu-Rituximab}$), and breast cancer ($^{177}\text{Lu-Trastuzumab}$). Furthermore, novel agents using Fluorine-18 ($^{18}\text{F-FDG}$) and Copper-64 ($^{64}\text{Cu}$) are expanding diagnostic reach into gastrointestinal, esophageal, and lung malignancies.
| Clinical Application | Radiopharmaceutical / Tool | Primary Medical Purpose |
| Prostate Cancer | $^{177}\text{Lu-PSMA-617}$ / $^{68}\text{Ga-PSMA-11}$ | Targeted therapy for advanced cases and high-precision PET diagnostics. |
| Neuroendocrine Tumors | $^{177}\text{Lu-DOTA-TATE}$ / $^{99\text{m}}\text{Tc-Hynic-TATE}$ | Targeted internal radiation and molecular SPECT imaging. |
| Cardiac Diagnostics | $^{99\text{m}}\text{Tc-MIBI}$ (sesta-MIBI) | Non-invasive myocardial perfusion imaging to assess blood flow. |
| Liver Malignancy | $^{90}\text{Y-Glass microspheres}$ (BhabhaSphere) | Selective internal radiation therapy (SIRT) for liver tumors. |
| Parkinson’s Disease | $^{99\text{m}}\text{Tc-TRODAT}$ | Brain imaging evaluating dopamine transporter levels. |
Expanding Equitable Access Across Regional Healthcare Centers
A central pillar of the DAE’s parliamentary update is the expansion of clinical patient services. The Radiation Medicine Centre (RMC) in Mumbai has long served as a focal point for nuclear medicine in India. To address geographic inequities, the Radiation Medicine Research Centre (RMRC) in Kolkata was made fully operational in early 2024.
As a state-of-the-art facility operating under BARC’s guidance, RMRC Kolkata delivers advanced diagnostic and therapeutic care to populations across Eastern and North-Eastern India—regions that historically faced barriers accessing specialized nuclear medicine.
In addition to cancer care, the DAE regularly produces over 18 different “cold kits” for Technetium-99m ($^{99\text{m}}\text{Tc}$). These kits allow local hospital staff to quickly formulate diagnostic tracers on-site for routine organ scans. For heart disease, the indigenous synthesis of sesta-MIBI ($^{99\text{m}}\text{Tc-MIBI}$) offers an affordable protocol for assessing myocardial blood flow in patients suffering from coronary artery disease.
Public Health Impact, Limitations, and Regulatory Context
From a public health perspective, localizing radioisotope recovery—such as harvesting Ruthenium-106, Caesium-137, and Strontium-90 from reprocessed high-level liquid waste—substantially lowers medical treatment costs.
Key Considerations for Patients & Providers
-
Short Half-Lives Demand Logistics: Radioactive isotopes decay rapidly (some within hours or days). Reliable transportation networks are essential to deliver products from reactors and cyclotrons to regional hospitals before potency drops.
-
Infrastructure Requirements: Facilities administering therapeutic isotopes must maintain specialized lead-shielded rooms, dedicated waste management protocols, and trained nuclear medicine specialists.
-
Not a Universal Cure: While targeted nuclear therapy offers significant palliative and survival benefits for advanced or resistant cancers, it is generally integrated alongside conventional approaches like surgery, external radiotherapy, and systemic therapies rather than completely replacing them.
“Indigenous production solves the critical bottleneck of supply and cost,” notes Dr. Rajesh Varma, a public health specialist not affiliated with the DAE. “However, the next step is building out regional infrastructure. Diagnostic equipment like PET-CT scanners and specialized nuclear medicine wards must continue expanding into tier-2 and tier-3 cities so that every patient can benefit from these domestic breakthroughs.”
What This Means for Patients
For patients and families navigating complex diagnoses, the expansion of domestic nuclear medicine means greater access to non-invasive diagnostics and targeted treatments with fewer systemic side effects than traditional therapies.
If you or a family member are undergoing evaluation for oncological, cardiac, or neurological conditions, consult your attending specialist to discuss whether nuclear imaging or targeted radionuclide therapy is appropriate for your specific treatment plan.
References & Sources
-
Government Announcement: Department of Atomic Energy (DAE), Press Information Bureau (PIB) Delhi. Parliament Question: Nuclear Technology in Medical Sectors. Published July 30, 2026.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
